Acquisition of Aquarius Biotechnologies, Inc. (now Matinas Biopharma Nanotechnologies, Inc.) (Details Textual) - USD ($) |
1 Months Ended | ||
|---|---|---|---|
Jan. 29, 2015 |
Dec. 31, 2016 |
Dec. 31, 2015 |
|
| Business Acquisition [Line Items] | |||
| Percentage Of Approval Shareholders | 100.00% | ||
| Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total | $ 2,873,035 | ||
| Contingent Consideration Classified as Equity, Fair Value Disclosure | $ 753,346 | ||
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent | $ 1,200,000 | $ 1,200,000 | |
| Aquarius Biotechnologies, Inc. [Member] | |||
| Business Acquisition [Line Items] | |||
| Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 4,608,020 | ||
| Business Combination, Contingent Consideration, Upon Achieving Certain Future Clinical Milestone, Number of Shares Issuable | 5,000,000 | ||
| Business Combination, Contingent Consideration, Upon Achieving Certain Future Regulatory Milestone, Number of Shares Issuable | 3,000,000 | ||
| Milestone Consideration Description | (i) 1,500,000 shares issuable upon the dosing of the first patient in a phase III trial sponsored by us for a product utilizing Aquarius proprietary cochleate delivery technology and (ii) 1,500,000 shares issuable upon FDA approval of the first NDA submitted by us for a product utilizing Aquarius proprietary cochleate delivery technology. The Company concluded that the contingent share issuance represented equity settled contingent consideration and have recorded the amounts to equity since inception. None of these milestones have yet been reached, and accordingly, as of December 31, 2016 |